A Dose Finding Study of IBI3016 in Mild to Moderate Hypertensive Patients
ConditionHypertension
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorInnovent Biologics (Suzhou) Co. Ltd.
About this trial
The purpose of this study is to evaluate the efficacy, safety and tolerability of IBI3016 or placebo, given subcutaneously, every 3 or 6 months, at different dose levels in patients with mild to moderate hypertension
Eligibility criteria
Qualifiers
Signed informed consent.
Males or females aged 18 to 75 years.
Diagnosis of primary hypertension without anti-HTN medication or with one anti-HTN medication
Mean sitting SBP ≥140 mmHg and < 170 mmHg measured by OBPM.
Disqualifiers
Known history of secondary hypertension.
Orthostatic hypotension.
Laboratory parameter assessments outside of range at screening：
Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) > 2× Upper Limit of Normal (ULN)
Trial design
Treatments tested in this trial
- IBI3016
- Placebo
Treatment groups
352 Participants
are divided into 6 treatment groups6
Treatment groupsSee each treatment group below.
Sponsors and collaborators
Source ClinicalTrials.gov